Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations

William L. Macias, Chief Medical Officer of Immunovant, Inc., sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On August 21, 2024, William L. Macias, the Chief Medical Officer of Immunovant, Inc., sold 2,907 shares of common stock at a weighted average price of $31.84.
• He also sold 120 shares of common stock at a weighted average price of $32.32.
• These sales were to cover tax withholding obligations related to the vesting of 7,051 restricted stock units (RSUs) on August 17, 2024.
• The sales were mandated by Immunovant's policy requiring tax obligations to be funded by a 'sell to cover' transaction.
• Following these transactions, Macias beneficially owns 368,332 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions by a company insider to cover tax obligations. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on the company's operations or financial condition.

Key Dates